M&A Speculation Fuels Rally in Viking Therapeutics Shares

Viking Therapeutics US92686J1060

Shares of Viking Therapeutics experienced a significant surge this week, propelled by renewed takeover speculation within the obesity drug sector. Comments from Novo Nordisk's leadership, coupled with signals from Viking's own CEO, have ignited investor interest in the potential for consolidation, driving notable trading activity.

The immediate catalyst was provided by Novo Nordisk CEO Mike Doustdar at the 44th J.P. Morgan Healthcare Conference in San Francisco. He emphasized that Novo remains open to acquisitions of varying sizes, provided they align strategically with the company's existing drug portfolio. In remarks to Bloomberg, Doustdar stated they could pursue a "very large" deal if a target was clearly superior to their current assets. This perspective is partly informed by Novo's withdrawal from the bidding for obesity specialist Metsera in November 2025, where Pfizer's winning offer reached $10 billion—a valuation Novo deemed too high.

In response, Viking's stock jumped as much as 17% during Wednesday's session, briefly surpassing the $35 mark. It closed the day with an 8.3% gain at $33.23. Trading volume spiked noticeably, with over 5 million shares changing hands compared to an average volume of approximately 3.5 million.

Viking's Leadership Acknowledges External Interest

Adding fuel to the speculative fire, Viking CEO Brian Lian, during his own presentation at the same conference on Monday, indicated that interest in the obesity space is more substantial than publicly apparent. He noted that multiple players are approaching the field. Lian reiterated a position from October, stating the company is "open" to external interest in its obesity program while also stressing its capability to continue development independently. He acknowledged that a larger partner could accelerate and simplify commercialization but framed it as an option rather than a necessity.

This sentiment has created a wave of optimism across the sector. Other companies in the metabolic disorder space also saw gains:
* Terns Pharmaceuticals (TERN) advanced roughly 10% to $38.03.
* Structure Therapeutics (GPCR) climbed about 6% to $85.16.

Broader Biotech M&A Trends Provide Context

This activity occurs against a backdrop of rising deal volumes in biotech and pharmaceuticals. According to Dealogic, globally announced biotech deals totaled $228.4 billion in 2025, up from $132.3 billion the previous year. The first two weeks of 2026 alone have seen deals worth $9.2 billion. A key driver is the approaching "patent cliff" for major pharmaceutical firms. For instance, U.S. patents for Novo Nordisk's Ozempic expire in 2031, while Merck's Keytruda loses exclusivity in 2028. Acquisitions in high-growth markets like obesity are viewed as a strategic method to offset these future revenue gaps.

Clinical Progress with VK2735

At the core of Viking's appeal is its lead drug candidate, VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. A Phase 2 study demonstrated an average weight reduction of up to 14.7% from baseline after 13 weeks. Two pivotal Phase 3 trials (VANQUISH-1 and VANQUISH-2) for the subcutaneous formulation are currently underway.

Recent corporate milestones include:
* Publication of Phase 2 VENTURE trial data in the journal Obesity on January 12.
* Completion of patient enrollment in a maintenance dose study on January 8.
* Appointment of Neil Aubuchon as Chief Commercial Officer on January 7.

The company aims to complete recruitment for VANQUISH-2 in Q1 2026. Additionally, data for an oral formulation of VK2735 is scheduled for presentation at the European Congress on Obesity in Q2 2026.

Financial Snapshot and Ownership

Viking Therapeutics currently carries a market valuation of approximately $3.98 billion. The consensus analyst rating stands at "Moderate Buy," with an average price target of $87.14. Individual targets range from $36 to $125 per share.

Institutional investors hold about 76% of the outstanding shares. Recent activity at the management level has involved share sales: CEO Brian Lian and CFO Greg Zante disposed of stock in early January. Over the past 90 days, insiders have sold a total of roughly 476,090 shares worth about $16 million.

Key Catalysts on the 2026 Horizon

With the J.P. Morgan conference concluding, further commentary from large pharma on M&A strategy remains possible. For Viking, several potential stock-moving events are anticipated this year:
* Results from the Phase 3 VANQUISH studies, expected in 2026.
* Presentation of Phase 2 data for the oral VK2735 formulation at the European Congress on Obesity in Q2.
* Findings from the maintenance dose study later in 2026.
* Submission of an IND application for the company's Amylin program in Q1 2026.

Given projections that the global market for obesity therapies will exceed $150 billion annually by the end of the decade, the interplay between clinical advancement and ongoing sector consolidation is likely to remain a central theme for the company's valuation.